Compare Gilead Sciences, Inc. (GILD) vs Reddit Inc (RDDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Reddit Inc — how do they compare? Gilead Sciences, Inc. trades at $136.8 (market cap $168.35B), while Reddit Inc trades at $153.63 (market cap $30.05B). The key difference: Gilead Sciences, Inc. is far larger — about 5.6× Reddit Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Reddit Inc pays none. Which is the better fit depends on your goals.
| GILD | RDDT | |
|---|---|---|
Market Cap | $168.35B | $30.05B |
Sector | Health | Media |
52-Week High | $155.80 | $270.71 |
52-Week Low | $110.56 | $121.84 |
Enterprise Value | $191.42B | $27.28B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Reddit (RDDT) trades at $152.50, down 3.91% amid a bearish technical signal despite strong Q2 2026 results showing 61% revenue growth and earnings beats. The stock faces selling pressure despite analyst consensus of $220.25 price target and 64% buy ratings. Recent CEO share sales and search traffic concerns have weighed on sentiment, though fundamentals remain robust with 31.35% net margins and positive cash flow trends.
The outlook remains bifurcated with strong fundamental performance contrasting with technical weakness. Investment opportunity lies in discounted valuation post-selloff and AI monetization potential, while risks include user growth sustainability and competitive pressures in social media landscape. The stock presents a growth-at-reasonable-price case if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Reddit Inc
Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.
Read more on RDDT →
